Serina Therapeutics, Inc.
New York Stock Exchange AmericanCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Steven A. Ledger
- Full Time Employees
- 12
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 601 Genome Way Huntsville AL United States of America 35806
- IPO Date
- Jan 21, 2000
- CIK
- 0001708599
- Website
- serinatherapeutics.com
- Similar Companies
- Business
- Serina Therapeutics, Inc. (NYSE American: SER) is a clinical-stage biotechnology company that develops proprietary POZ Platform polymer technology to create long-acting drug conjugates for neurological diseases, pain management, and other indications including RNA-based therapeutics and antibody-drug conjugates; its lead product candidate SER-252 (POZ-apomorphine) provides continuous dopaminergic stimulation via twice-weekly subcutaneous injection for advanced Parkinson's disease; additional candidates comprise SER-270 (POZ-VMAT2 inhibitor) for tardive dyskinesia, SER-214 (POZ-rotigotine) for early Parkinson's disease and restless leg syndrome, SER-227 for long-acting pain relief, and SER-228 for epilepsy; the POZ technology offers near-linear release kinetics, reduced immunogenicity versus PEG polymers, and versatile administration via IV, SC, or IM routes. Founded in 2006 and headquartered at 601 Genome Way, Suite 2001, Huntsville, Alabama, the company operates primarily in the United States with global clinical trial plans including Australia and pursues a 505(b)(2) regulatory pathway to accelerate development leveraging established molecules. Recent developments include securing up to $20 million in convertible note and warrant financing in September 2025 with an initial $5 million tranche drawn to fund the registrational Phase 1b trial of SER-252, submission of an IND application to the FDA and receipt of Human Research Ethics Committee approval in Australia for SER-252 with first patient dosing on track for Q4 2025, FDA alignment in August 2025 confirming the SER-252 trial design as registrational under 505(b)(2), advancement of SER-270 into development for tardive dyskinesia in July 2025, and launch of an enhanced corporate communications platform in October 2025.
Serina Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates
Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease
Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026
Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026
Serina Therapeutics to Present at the 5th LNP Formulation & Process Development Summit
Serina Therapeutics Announces NYSE American Acceptance of Continued Listing Compliance Plan
Serina Therapeutics Reports Full Year 2025 Financial Results and Recent Business Highlights
Serina Therapeutics to Present at the 38th Annual Roth Conference
Stock Market Today: S&P 500, Dow Futures Down Ahead Of 'Triple Witching' As Iran Warns Of 'Zero Restraint'—FedEx, Super Micro Computer In Focus
Serina Therapeutics (SER) Stock Surges Over 39% After Hours— Here's Why
Serina Therapeutics Secures up to $30 Million in Private Placement to Advance Registrational Trial of SER-252 for Advanced Parkinson's Disease
Serina Therapeutics Announces Dosing of First Patient in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease
Serina Therapeutics Announces First Patient Enrolled in Phase 1b Registrational Trial of SER-252 for Advanced Parkinson's Disease
Registration Is Now Open For Tribe Public's CEO Presentation and Q&A Webinar Event
What Sparked Serina Therapeutics (SER) 35% After-Hours Surge?
Serina Therapeutics Announces FDA Clearance of IND Application for SER-252 for the Treatment of Advanced Parkinson's disease
Serina Therapeutics Receives NYSE Deficiency Notification Regarding Shareholders' Equity
Serina Therapeutics Strengthens Leadership Team with Appointment of Dr. Joshua Thomas as VP, Head of Chemistry
Serina Therapeutics Submits Complete Response to FDA Clinical Hold Letter for SER-252 Program
Serina Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights